Summary of the AMA’s Efforts to Address Substance Use and Mental Health Disorders
This text details the American Medical Association’s (AMA) ongoing efforts to combat the opioid crisis and broader substance use/mental health challenges. Here’s a breakdown of the key points:
Core Issues & AMA Positions:
* Opioid Use Disorder (OUD) Treatment:
* Methadone: Recognized as life-saving but underutilized due to stigma, regulations, and insurance hurdles. The AMA advocates for eliminating prior authorization and expanding access beyond specialized opioid treatment programs.
* Buprenorphine: Advocating for clarification from the FDA that higher doses can be appropriate for patients. Working with a coalition to address DEA policies hindering dispensing.
* Naloxone: Crucial for overdose prevention. The AMA supports over-the-counter access,ED distribution,and community programs.
* Emerging Threats: Increasing polysubstance use (stimulants, xylazine, kratom, tianeptine, inhalants) and cannabis-use disorder are raising concerns, requiring increased surveillance and research.
* Mental Health Parity: Enforcing laws requiring equal coverage for mental health and substance use disorders as physical health conditions is a top priority.
* Pain Management: Removing barriers to treatment for both pain and substance use disorders is essential.
Key Policy Priorities & Actions:
* State-Level Advocacy: The AMA is actively working with states to:
* Strengthen enforcement of mental health/substance use parity laws with penalties for non-compliance.
* Remove barriers to medications for OUD (prior authorization, buprenorphine dosage limits).
* Expand naloxone access through various channels.
* New Tools & Resources:
* Mental health Parity Index: A data visualization tool (developed with The Kennedy Forum and Third Horizon) to analyze insurance plan compliance with mental health parity laws.
* Collaborative Efforts (2025 Highlights):
* Partnering with medical societies to influence FDA policy on buprenorphine dosage.
* Working with pharmacy coalitions to address DEA concerns regarding buprenorphine dispensing.
* Supporting state laws in Colorado, Illinois, Virginia, and Washington related to pain care, parity, and naloxone access.
* Advancing initiatives to improve naloxone access and protect patients with pain.
Overall Goal: The AMA aims to remove barriers to care, reduce stigma, and ultimately save lives by increasing access to evidence-based treatment for substance use and mental health disorders. They emphasize a collaborative approach involving physicians, policymakers, insurers, and community organizations.